Biovica and the international breast cancer study group & breast international group in collaboration to improve outcome for women with breast cancer

Biovica’s DiviTum™ technology has been selected by the International Breast Cancer Study Group (IBCSG, Bern) and the Breast International Group (BIG, Brussels) to be part of a state of the art trial, studying the effects of palbociclib, a promising new cancer drug. The study, named PYTHIA, will follow women with advanced breast cancer being treated [...]

2017-01-03T10:51:32+00:00 December 1st, 2015 08:45|Regulatory|